Rohto Pharmaceutical Co., Ltd. will acquire up to 1,500,000 shares of treasury stock through market purchases from March 27, 2026 to December 31, 2026, with a total purchase price of up to 3 billion yen to improve capital efficiency.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4527","jir_company_name":"Rohto Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-26","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4527-20260326-01.pdf","jir_short_summary":"Rohto Pharmaceutical Co., Ltd. will acquire up to 1,500,000 shares of treasury stock through market purchases from March 27, 2026 to December 31, 2026, with a total purchase price of up to 3 billion yen to improve capital efficiency.","jir_summary":"### Overview of Capital Policy\nRohto Pharmaceutical Co., Ltd. has resolved to acquire treasury stock aiming to improve capital efficiency and implement agile capital policies. The target shares are the company's common stock, with an upper limit of 1,500,000 shares (0.66% of total issued common shares), and a total acquisition price of up to 3 billion yen. The acquisition period is from March 27, 2026 to December 31, 2026, and the acquisition method is market purchase on the Tokyo Stock Exchange.\n\n### Impact on Shareholders and Current Status\nAs of March 26, 2026, the total number of issued shares is 236,178,310 shares (including treasury stock), the number of treasury shares is 10,213,970 shares, and the total issued shares excluding treasury stock is 225,964,340 shares. This share buyback plans to acquire approximately 0.66% of the total issued shares and is expected to contribute to improving capital efficiency. Although specific fund usage is not stated, the objective is to implement agile capital policies.","jir_financial_highlights":"Type of shares subject to acquisition: Our common stock (Unknown)\nTotal number of shares to be acquired: 1,500,000 shares (upper limit) (Ratio to total issued common shares (excluding treasury stock): 0.66%)\nTotal acquisition price: 3 billion yen (upper limit) (Unknown)\nAcquisition period: From March 27, 2026 to December 31, 2026 (Unknown)\nAcquisition method: Market purchase on the Tokyo Stock Exchange (Unknown)\nTotal issued shares (including treasury stock): 236,178,310 shares (Unknown)\nNumber of treasury shares: 10,213,970 shares (Unknown)\nTotal issued shares (excluding treasury stock): 225,964,340 shares (Unknown)","jir_category":"","jir_hashtags":"#RohtoPharmaceuticalCoLtd, #ShareBuyback, #CapitalPolicy, #JapaneseStocks","jir_key_figures":"Maximum number of shares to be acquired: 1,500,000 shares (0.66% of total issued common shares)\nMaximum acquisition price: 3 billion yen\nAcquisition period: From March 27, 2026 to December 31, 2026","jir_meta_title":"Rohto Pharmaceutical Approves Share Buyback of up to 1,500,000 Shares and 3 Billion Yen (2026)","jir_meta_description":"On March 26, 2026, Rohto Pharmaceutical Co., Ltd. resolved to acquire up to 1,500,000 shares of treasury stock (0.66%) through market purchases with a maximum total purchase price of 3 billion yen to improve capital efficiency.","jir_og_title":"Rohto Pharmaceutical Announces Share Buyback (2026)","jir_og_description":"Rohto Pharmaceutical will acquire up to 1,500,000 shares of treasury stock with a cap of 3 billion yen from March 27, 2026 to December 31, 2026 to enhance capital efficiency.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7770,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-36874","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n